Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial
Plasma exposures after single and multiple CAZ/AVI doses in neonates and young infants < 3 months old (37.5 [30/7.5] mg/kg/dose for > 28 days; 25 [20/5] mg/kg/dose for ≤ 28 days) were similar to approved doses for older children. The safety profile of CAZ/AVI was as expected based on previous observations. Study funded by Pfizer. Trial registration: NCT04126031.
Authors
- John S. Bradley (ORCID: https://orcid.org/0000-0002-3835-5064)
- Gregory G. Stone (ORCID: https://orcid.org/0000-0001-6115-2567)
- Elena Soto (ORCID: https://orcid.org/0009-0005-0999-1351)
- Emmanuel Roilides (ORCID: https://orcid.org/0000-0002-0202-364X)
- Margaret Tawadrous (ORCID: https://orcid.org/0000-0002-6815-2647)
- Shweta Kamat (ORCID: https://orcid.org/0000-0003-3584-5014)
- Paurus Irani
- Jean Li Yan
- Richard D. England
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Aristotle University of Thessaloniki (GR)
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- Pfizer (India) (IN)
- Hippocration General Hospital (GR)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1093/jpids/piaf028
- Citations
- 4
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 2.36
Funders
- Pfizer
- AbbVie